OR WAIT 15 SECS
© 2021 MJH Life Sciences™ , Dermatology Times and Multimedia Medical, LLC. All rights reserved.
NovaBay Pharmaceuticals has received $2.6 million from partner Galderma for the clinical advancement of NovaBay’s “non-antibiotic, anti-infective” Aganocide compound NVC-422, a topical formulation for impetigo treatment.
Related Content:
News